McBride, A., Macdonald, K., Fuentes-Alburo, A., & Abraham, I. (2021). Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. 24(1). https://doi.org/10.1080/13696998.2021.1928515

Xu, Y.- ming, Madasu, C., Liu, P., Wijeratne, E., Dierig, D., White, L., Molnár, I., & Gunatilaka, A. (2021). Cycloartane- and Lanostane-Type Triterpenoids from the Resin of Parthenium argentatum AZ-2, a Byproduct of Guayule Rubber Production. 6(23).

Muralidharan, P., Acosta, M., Gomez, A., Grijalva, C., Tang, H., Yuan, J., & Mansour, H. (2021). Design and Comprehensive Characterization of Tetramethylpyrazine (TMP) for Targeted Lung Delivery as Inhalation Aerosols in Pulmonary Hypertension (PH): In Vitro Human Lung Cell Culture and In Vivo Efficacy. 10(3). https://doi.org/10.3390/antiox10030427

Kim, M., & Abraham, I. (2021). Determinants of the Higher Prevalence and Severity of Subjective Cognitive Impairment in Cancer Patients Compared to Healthy Subjects: Fatigue and Stress. 30(6). https://doi.org/10.1177/1054773820957474

Sutar, Y., Fulton, S., Paul, S., Altamirano, S., Mhatre, S., Saeed, H., Patel, P., Mallick, S., Bhat, R., Patravale, V., Chauhan, D., Nielsen, K., & Date, A. (2021). Docusate-Based Ionic Liquids of Anthelmintic Benzimidazoles Show Improved Pharmaceutical Processability, Lipid Solubility, and Activity against . 7(9). https://doi.org/10.1021/acsinfecdis.1c00063

McQuade, B., & Campbell, P. (2021). Drug Prescribing: Drug-Drug Interactions. 508.

McQuade, B., & Campbell, P. (2021). Drug Prescribing: Polypharmacy and Deprescribing. 508.

Mohzari, Y., Alshuraim, R., Asdaq, S., Aljobair, F., Alrashed, A., Alsowaida, Y., Alamer, A., Munjem, M., Musawa, M., Hatata, M., Alzaaqi, M., Binrokan, A., Alajlan, S., Abraham, I., & Alamer, A. (2021). Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis. 15(1). https://doi.org/10.1016/j.jiph.2021.11.006

Alamer, A., Alrashed, A., Alfaifi, M., Alosaimi, B., AlHassar, F., Almutairi, A., Howaidi, J., Almutairi, A., Mohzari, Y., Sulaiman, T., Al-Jedai, A., Alajami, H., Alkharji, F., Alsaeed, A., Alali, A., Baredhwan, A., Abraham, I., & Almulhim, A. (2021). Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. 37(7). https://doi.org/10.1080/03007995.2021.1920900

Grace, K., Larriva, M., Steiner, H., Marupuru, S., Campbell, P., Patterson, H., Cropp, C., Quinn, D., Klimecki, W., Nix, D., Warholak, T., & Karnes, J. (2021). Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial. 14(6). https://doi.org/10.1111/cts.13121

Chinthammit, C., Axon, D., Mollon, L., Taylor, A., Pickering, M., Black, S., Warholak, T., & Campbell, P. (2021). Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study. 27(1). https://doi.org/10.18553/jmcp.2021.27.1.064

Marupuru, S., Dhatt, H., Bingham, J., & Warholak, T. (2021). Evaluation of a Novel Pharmacist-Delivered Adherence Improvement Service via Telehealth. 9(3). https://doi.org/10.3390/pharmacy9030140

Alkhatib, N., Sweitzer, N., Lee, J., Erstad, B., Slack, M., Gharaibeh, M., Karnes, J., Klimecki, W., Ramos, K., & Abraham, I. (2021). Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. 21(2). https://doi.org/10.1007/s40256-020-00425-x

Lott, B., Anderson, E., Zapata, L., Cooley, J., Forbes, S., Taylor, A., Manygoats, T., & Warholak, T. (2021). Expanding pharmacists’ roles: Pharmacists’ perspectives on barriers and facilitators to collaborative practice. 61(2). https://doi.org/10.1016/j.japh.2020.11.024

Ray, A.-M., Salim, N., Stevens, M., Chitre, S., Abdeen, S., Washburn, A., Sivinski, J., O’Hagan, H., Chapman, E., & Johnson, M. (2021). Exploiting the HSP60/10 chaperonin system as a chemotherapeutic target for colorectal cancer. 40. https://doi.org/10.1016/j.bmc.2021.116129

Schmidlin, C., Tian, W., Dodson, M., Chapman, E., & Zhang, D. (2021). FAM129B-dependent activation of NRF2 promotes an invasive phenotype in BRAF mutant melanoma cells. 60(5). https://doi.org/10.1002/mc.23295

Vallorz, E., Blohm-Mangone, K., Schnellmann, R., & Mansour, H. (2021). Formoterol PLGA-PEG Nanoparticles Induce Mitochondrial Biogenesis in Renal Proximal Tubules. 23(4). https://doi.org/10.1208/s12248-021-00619-4

Ambrose, A., & Chapman, E. (2021). Function, Therapeutic Potential, and Inhibition of Hsp70 Chaperones. 64(11). https://doi.org/10.1021/acs.jmedchem.0c02091

Sivinski, J., Ambrose, A., Panfilenko, I., Zerio, C., Machulis, J., Mollasalehi, N., Kaneko, L., Stevens, M., Ray, A.-M., Park, H., Wu, C., Hoang, Q., Johnson, M., & Chapman, E. (2021). Functional Differences between E. coli and ESKAPE Pathogen GroES/GroEL. 12(1). https://doi.org/10.1128/mBio.02167-20

Hamarneh, D., Alkhatib, N., Denhaerynck, K., Vancayzeele, S., Brié, H., Macdonald, K., & Abraham, I. (2021). Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients. 37(3). https://doi.org/10.1080/03007995.2021.1877124

Axon, D., Marupuru, S., & Vaffis, S. (2021). Health Costs of Older Opioid Users with Pain and Comorbid Hypercholesterolemia or Hypertension in the United States.

Axon, D., Marupuru, S., & Vaffis, S. (2021). Health Costs of Older Opioid Users with Pain and Comorbid Hypercholesterolemia or Hypertension in the United States. 9(2). https://doi.org/10.3390/diseases9020041

Alkhatib, N., Sun, B., Denhaerynck, K., Hamarneh, D., Van Camp, Y., Villa, L., Brié, H., Vancayzeele, S., Macdonald, K., & Abraham, I. (2021). Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients. 37(1). https://doi.org/10.1080/03007995.2020.1853082

Campbell, P., Axon, D., Taylor, A., Smith, T., Pickering, M., Black, S., Warholak, T., & Chinthammit, C. (2021). Hypertension, cholesterol and diabetes medication adherence, health care utilization and expenditure in a Medicare Supplemental sample. 100(35). https://doi.org/10.1097/MD.0000000000027143

Almutairi, A., Erstad, B., McBride, A., Slack, M., & Abraham, I. (2021). Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data. 20(4). https://doi.org/10.1080/14740338.2021.1877272

Shroff, R., Chalasani, P., Wei, Y., Pennington, D., Quirk, G., Schoenle, M., Peyton, K., Uhrlaub, J., Ripperger, T., Jergović, M., Dalgai, S., Wolf, A., Whitmer, R., Hammad, H., Carrier, A., Scott, A., Nikolich-Žugich, J., Worobey, M., Sprissler, R., … Bhattacharya, D. (2021). Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy. https://doi.org/10.1101/2021.05.13.21257129

Wang, L., Little, N., Chen, Q., Lambesis, K., Le, D., Han, W., Scott, A., & Lu, J. (2021). Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. https://doi.org/10.1038/s41565-021-00950-z

Eedara, B., Alabsi, W., Encinas-Basurto, D., Polt, R., Ledford, J., & Mansour, H. (2021). Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection. 13(7). https://doi.org/10.3390/pharmaceutics13071077

Campbell, P., Vraney, J., Oman, N., Xie, C., & Erstad, B. (2021). Initiation of Oseltamivir in Critically Ill Patients: Variations in Prescribing Practices. 55(2). https://doi.org/10.1177/1060028020942513

Fazel, M., AlRawashdh, N., Alamer, A., Curiel-Lewandrowski, C., & Abraham, I. (2021). Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma. 21(12). https://doi.org/10.1080/14712598.2022.1998450